Preliminary results from a nationwide adult cardiology perspective for pulmonary hypertension: RegiStry on clInical outcoMe and sUrvival in pulmonaRy hypertension Groups (SIMURG)
1Department of Cardiology, Kartal Koşuyolu Heart Education and Research Hospital; İstanbul-Turkey
2Department of Cardiology, Faculty of Medicine, Marmara University; İstanbul-Turkey
3Department of Cardiology, Cardiology Institute, İstanbul University; İstanbul-Turkey
4Department of Cardiology, Faculty of Medicine, Hacettepe University; Ankara-Turkey
5Department of Cardiology, Faculty of Medicine, Dokuz Eylül University; İzmir-Turkey
6Department of Cardiology, Cerrahpaşa Medical Faculty, İstanbul University; İstanbul-Turkey
7Department of Cardiology, Faculty of Medicine, Erzurum Atatürk University; Erzurum-Turkey
8Department of Cardiology, Faculty of Medicine, Fırat University; Elazığ-Turkey
9Department of Cardiology, Faculty of Medicine, Dicle University; Diyarbakır-Turkey
10Department of Cardiology, Faculty of Medicine, Uludağ University; Bursa-Turkey
11Department of Cardiology, Faculty of Medicine, Gazi University; Ankara-Turkey
12Department of Cardiology, Faculty of Medicine, Ege University; İzmir-Turkey
13Department of Cardiology, Faculty of Medicine, Karadeniz Technical University (KTU); Trabzon-Turkey
14Department of Cardiology, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Center; İstanbul-Turkey
15Department of Cardiology, Faculty of Medicine, Gaziantep University; Gaziantep-Turkey
16Department of Cardiology, Faculty of Medicine, İnönü University; Malatya-Turkey
17Department of Cardiology, Ankara Yüksek İhtisas Hospital; Ankara-Turkey
18Department of Cardiology, Faculty of Medicine, Çukurova University; Adana-Turkey
19Department of Cardiology, Faculty of Medicine, Cumhuriyet University; Sivas-Turkey
20Department of Cardiology, Faculty of Medicine, Erciyes University; Kayseri-Turkey
Anatol J Cardiol 2017; 18(4): 242-250 PubMed ID: 29076824 PMCID: 5731519 DOI: 10.14744/AnatolJCardiol.2017.7549
Full Text PDF

Abstract

Objective: The present study was designed to evaluate the characteristics of pulmonary hypertension (PH) and adult cardiology practice patterns for PH in our country.
Methods: We evaluated preliminary survey data of 1501 patients with PH (females, 69%; age, 44.8±5.45) from 20 adult cardiology centers (AdCCs).
Results: The average experience of AdCCs in diagnosing and treating patients with PH was 8.5±3.7 years. Pulmonary arterial hypertension (PAH) was the most frequent group (69%) followed by group 4 PH (19%), group 3 PH (8%), and combined pre- and post-capillary PH (4%). PAH associated with congenital heart disease (APAH-CHD) was the most frequent subgroup (47%) of PAH. Most of the patients’ functional class (FC) at the time of diagnosis was III. The right heart catheterization (RHC) rate was 11.9±11.6 per month. Most frequently used vasoreactivity agent was intravenous adenosine (60%). All patients under targeted treatments were periodically for FC, six-minute walking test, and echo measures at 3-month intervals. AdCCs repeated RHC in case of clinical worsening (CW). The annual rate of hospitalization was 14.9±19.5. In-hospital use of intravenous iloprost reported from 16 AdCCs in CWs. Bosentan and ambrisentan, as monotreatment or combination treatment (CT), were noted in 845 and 28 patients, respectively, and inhaled iloprost, subcutaneous treprostinil, and intravenous epoprostenol were noted in 283, 30, and four patients, respectively. Bosentan was the first agent used for CT in all AdCCs and iloprost was the second. Routine use of antiaggregant, anticoagulant, and pneumococcal and influenza prophylaxis were restricted in only two AdCCs.
Conclusion: Our nationwide data illustrate the current status of PH regarding clinical characteristics and practice patterns.